Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

IND Over POC: The New Sweet Spot For Biopharma Dealmaking

Related Content

Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns

Mar 01 2011

Atlas, CMEA Test New Biotech Model

Apr 01 2011

The A-List: 2010's Trend-Shaping Series A Financings

Jan 01 2011

Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model

Mar 01 2011

Start-Up Previews (10/2011)

Oct 01 2011

Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier

Oct 01 2010

The $100 Million IND

Nov 01 2006

Spurred By Necessity, Industry And Academia Are Learning To Share

Oct 03 2011

Biotech Ventures Forth: Third Rock Rolls Out $426M Fund, Relypsa Reloads

Sep 13 2010

Related Companies

Reata Pharmaceuticals, Inc.

Abbott

Blueprint Medicines Corporation

Plexxikon, Inc.

Daiichi Sankyo Co., Ltd.

Bayer AG

OncoMed Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated

Alios BioPharma

Forma Therapeutics Inc.

Roche Holding AG

Genentech, Inc.

Nimbus Therapeutics, Inc.

More from In Vivo Archive

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window